NARACHI MICHAEL 4
4 · Ultragenyx Pharmaceutical Inc. · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
Ultragenyx (RARE) Director Michael Narachi Receives RSUs & Option
What Happened
Michael Narachi, a director of Ultragenyx Pharmaceutical Inc. (RARE), received equity awards reported on 2026-05-14: 7,751 restricted stock units (RSUs) and a derivative award/option covering 14,058 shares. Both awards show an acquisition price of $0.00, so no cash was paid. The filing shows no immediate sale — these are awards that vest in the future rather than open-market purchases or sales.
Key Details
- Transaction date: 2026-05-14; Form 4 filed 2026-05-18 (filed within the typical 2-business-day reporting window).
- Awards: 7,751 RSUs (grant) and 14,058-share derivative/option (grant) at $0.00 (total cash paid = $0).
- Vesting: Both awards vest in full on the earlier of the Company’s next Annual Meeting of Stockholders or May 14, 2027 (Footnotes F1–F2).
- Shares owned after transaction: not specified in the provided filing excerpt.
- No 10b5-1, tax-withholding, or immediate cashless-sale indicators noted in the provided data.
Context
RSUs and option/derivative grants are compensation awards that convert to stock only after vesting; they do not indicate an immediate market purchase or sale. For retail investors, such grants are routine director compensation and do not by themselves signal buying or selling intent.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-14+7,751→ 40,441 total - Award
Stock Option (Right to Buy)
[F2]2026-05-14+14,058→ 14,058 totalExercise: $25.80Exp: 2036-05-14→ Common Stock (14,058 underlying)
Footnotes (2)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
- [F2]The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.